Senti Biosciences Holdings, Inc. SNTI PHARMA
Company Overview
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR -81.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -81.15% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -79.49% |
| 6 Months: | -67.54% |
| 3 Months: | -66.48% |
| 1 Month: | -10.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)29.84 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -81.2% CAGR over 5 years.
- Trading 86.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SNTI Senti Biosciences Holdings, Inc. PHARMA | 0.32 | -0.19 | $9.97M | 0.00% | - | - | -81.15% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 778.00K | 926.00K | 854.00K | 1.11M | 1.52M | - | 1.04M | 687.00K | 255.00K | - | 0 | 0 | 0 | - | 0 | 0 | 0 | 22.00K | 16.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.40M | 16.80M | 16.95M | 13.61M | 11.51M |
| Operating Income | - | -9.00M | -11.42M | -11.76M | -21.77M | -14.75M | - | -14.96M | -15.19M | -43.88M | - | -16.30M | -13.36M | -15.21M | - | -16.40M | -16.80M | -16.95M | -13.58M | -11.50M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.47M | -14.78M | -16.27M | -12.69M | -10.81M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.11M | -14.73M | -18.13M | -14.47M | -4.22M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -21.00M | -12.01M | -11.41M | -11.81M | -11.55M | -16.64M | -58.21M | -18.72M | -18.70M | -14.92M | -71.06M | -12.11M | -11.20M | -28.87M | - | -14.11M | -14.73M | -18.13M | -14.47M | -4.22M |
| Diluted EPS | - | -4.13 | -3.90 | -3.72 | -0.86 | -0.38 | - | -0.42 | -4.22 | -3.36 | - | -2.65 | -2.45 | -6.31 | - | -1.41 | -0.56 | -0.69 | -0.53 | -0.14 |
| R&D Expense | - | 5.24M | 5.41M | 7.60M | 9.25M | 6.52M | - | 7.06M | 6.88M | 9.09M | - | 8.78M | 9.15M | 8.65M | - | 9.28M | 10.03M | 10.52M | - | 5.28M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 3.29M | 1.98M | 0 | 22.00K |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 65.37M | 68.74M | 60.73M | 63.75M |
| Operating Income | - | -62.08M | -66.77M | -60.73M | -63.73M |
| EBITDA | - | -58.16M | -61.34M | -56.89M | -60.09M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -49.66M | -83.41M | -52.79M | -61.44M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -58.21M | -71.06M | -52.79M | -61.44M |
| Diluted EPS | - | -22.30 | -16.01 | -12.03 | -2.73 |
| R&D Expense | 21.96M | 28.14M | 32.15M | 34.36M | 37.59M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Feb 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 180.79M | 119.48M | 97.84M | 51.22M |
| Current Assets | - | - | - | 102.58M | 71.20M | 58.96M | 23.27M |
| Cash & Equivalents | - | 0 | - | 57.62M | 35.93M | 48.28M | 16.42M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 626.00K | 112.00K | 159.00K | 323.00K |
| Total Liabilities | - | - | - | 53.53M | 52.57M | 72.19M | 45.63M |
| Current Liabilities | - | - | - | 18.05M | 12.67M | 13.15M | 13.97M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 37.09M | 37.67M | 33.54M | 28.89M |
| Total Equity | -58.71M | 0 | - | 127.26M | 66.91M | 25.65M | 5.59M |
| Shares Outstanding | - | - | - | 4.41M | 4.57M | 4.83M | 30.88M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -34.90M | -52.40M | -41.40M | -43.44M |
| Investing Cash Flow | - | -81.96M | 30.08M | 34.00K | -184.00K |
| Financing Cash Flow | - | 118.55M | 779.00K | 53.73M | 11.76M |
| Capital Expenditure | - | -41.37M | -12.04M | -26.00K | -196.00K |
| Free Cash Flow | - | -76.27M | -64.43M | -41.42M | -43.64M |
| Net Change in Cash | - | 1.70M | -21.54M | 12.37M | -31.87M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -1,889.3% | -3,375.4% | - | -289,668.2% |
| Net Margin % | - | -1,771.5% | -3,592.4% | - | -279,263.6% |
| ROE % | - | -45.7% | -106.2% | -205.8% | -1,099.3% |
| ROCE % | - | -38.1% | -62.5% | -71.7% | -171.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | 2.85% | 888.00K | $284.16K |
| 2 | Vanguard Capital Management LLC | 1.73% | 537.50K | $172.00K |
| 3 | Geode Capital Management, LLC | 0.60% | 187.06K | $59.86K |
| 4 | Citadel Advisors Llc | 0.34% | 107.10K | $34.27K |
| 5 | Vanguard Fiduciary Trust Co | 0.29% | 91.19K | $29.18K |
| 6 | Jane Street Group, LLC | 0.17% | 52.53K | $16.81K |
| 7 | Menlo Ventures Management, L.P. | 0.11% | 35.74K | $11.44K |
| 8 | Northern Trust Corporation | 0.10% | 32.15K | $10.29K |
| 9 | Xtx Topco Ltd | 0.08% | 23.61K | $7.55K |
| 10 | Virtu Financial LLC | 0.07% | 22.80K | $7.29K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SNTI
Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiTkFVX3lxTE5kN3ZBN3pvX1pBSUc2eWdveFF4NG1jZGNxcTdrNWZyd3FqVm1QS2RlcW5iRkZ1OF9BTGtKTzFBX0I2TngybzJwbHU4a3ZKUQ?oc=5" target="_blank">Senti Biosciences Holdings Inc. (SNTI) Stock Price | Live Quo…
SNTI Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1UUFY0UDBBSFUwY3R6N0NYOGRzMGxuMk9aQUhRZ0lpenNFRW1wVFQ5bnZUcVh5M1VIREdhZXZLOHpSVFZFRzFPU0ZOZ3FOb1ctV3BVNEE4ZC1QeDNoNGJFbmt4MW9uVFdiSVdPXy1RY0E4TG53cDhJa2pB?oc=5" target="_blank">SNT…
Senti Biosciences Inc (NASDAQ: SNTI) Share Price, SNTI Stock News, SNTI Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE51MEdiLVZXaXZSdWJyWWZSUWQ4ZGJSa0U3LUx6RncyRGRwVHgzRk52N3VoTTEzNjdkQlNmYWJ5dHVvYUFnd1NHWngtOEZuTFZUQmZkWkd3?oc=5" target="_blank">Senti Biosciences Inc (NASDAQ: SNTI) Share Price, S…
Senti Bio Stockholders Could Receive Up to $60M From SENTI-202 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPZVBwOU1zQ3JMWHJvT3dDMFU1RHFtZkM3SDl2WXlmdTh6WkY1ZWNmZDlETU1XaHJDY29KVGJ2NmliZUZZaWJ2NVV1dVpzb2N3bjNPVkdzUWltOUowZS00M2hIZ3FPaGYxQmF5bFg1STNpV2VVQlFULUtQWnNrT1hVTWJ6ZWVFR21IN3k2Vm…
SNTI - Senti Biosciences Holdings Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBzZ0ZiREN3WlF3cjM5TUpTeS0wWTNDZlRIUlM1X1JkUTlFWjVhLXdHQUIxckFyTDRQWXRBT2VWVVJiMTVfcUE?oc=5" target="_blank">SNTI - Senti Biosciences Holdings Inc Stock Price and Quote</a> &nb…
The market is filled with gapping stocks in Wednesday's session. - ChartMill
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQUjZSbHpVV2dNWDNxVTk5eVhhWnZScldSWFdnZ1BWSXVNWGx0Q3RqX1lnT2JRMnZTUlRrOXNucWxjRDlsRzFNU21jd3BCWm1fcDd6WTREUFlZN2tZVXpQbkRjS2xIcW1XSzc0eHFpZHpsN285cEptcEFfVEkxUGZxYTE5WXdWOTVOVC1Gen…
SNTI — Frequently Asked Questions
What is the current share price of Senti Biosciences Holdings, Inc. (SNTI)?
As of 2026-09-19 21:16 PDT, Senti Biosciences Holdings, Inc. (SNTI) trades at $0.32 on NasdaqCM. Its 52-week range is $0.32 to $2.39.
What is the market capitalisation of SNTI?
Senti Biosciences Holdings, Inc. (SNTI) has a market capitalisation of $9.97M on NasdaqCM.
What is the P/E ratio of SNTI?
SNTI trades at a trailing price-to-earnings (P/E) ratio of -0.19. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -2.94.
Is SNTI a good stock to buy?
This page provides a data-driven analysis of Senti Biosciences Holdings, Inc. (SNTI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.